Business Context and Reporting Period
Company: Histogenics Corporation (f/k/a Ocugen, Inc. in metadata, but filing identifies Histogenics Corporation)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2014
Business Overview: Histogenics is a clinical-stage regenerative medicine company focused on the musculoskeletal segment. Its lead product candidate, NeoCart, is an autologous cartilage tissue implant currently in a Phase 3 clinical trial for the treatment of full-thickness cartilage defects in the knee. The company has no approved products and generated no product revenue in 2014. Operations are conducted primarily in Waltham, Massachusetts, with a subsidiary in Israel.
Key Financial Metrics
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $0 | $8,000 |
| Net Loss | $(22.8) million | $(25.7) million |
| Research & Development Expenses | $25.9 million | $11.9 million |
| General & Administrative Expenses | $6.7 million | $4.8 million |
| Cash and Cash Equivalents (Year End) | $58.1 million | $8.7 million |
| Accumulated Deficit | $(133.5) million | $(110.7) million |
| Debt | $1.75 million (Equipment Loan) | $0 |
Note: Figures in millions unless otherwise noted. Revenue in 2013 was from a terminated collaboration agreement.
Material Changes vs. Prior Period
- Initial Public Offering (IPO): Completed on December 3, 2014, raising approximately $62.8 million in net proceeds. This significantly increased cash reserves from $8.7 million in 2013 to $58.1 million in 2014.
- Revenue Cessation: Collaboration revenue dropped to zero in 2014 following the termination of the AT Grade license agreement in 2012 (final revenue recognized in 2013).
- Increased R&D Spend: R&D expenses increased by $14.0 million (117%) year-over-year. This was primarily driven by a $10.0 million non-cash up-front technology access fee paid to Intrexon Corporation and increased costs for the NeoCart Phase 3 clinical trial.
- Other Income/Expense: Shifted from a net expense of $(8.9) million in 2013 to net income of $9.9 million in 2014. This was largely due to a $10.0 million gain from the change in fair value of warrant and other liabilities upon the IPO.
- Debt: Entered into a $1.75 million equipment loan with Silicon Valley Bank in July 2014.
Guidance, Outlook, and Risks
Outlook and Guidance
- Cash Runway: Management believes current cash resources ($58.1 million) are sufficient to fund operations through the middle of 2017.
- Clinical Trial Timeline: Enrollment for the NeoCart Phase 3 trial is expected to be completed by the end of the first half of 2016. The company anticipates submitting a Biologics License Application (BLA) to the FDA in the second half of 2017, with potential approval in 2018.
- Manufacturing Transition: The company is transitioning the manufacturing of critical raw materials (collagen, scaffold, bioadhesive) from third-party vendors to its own facility in Lexington, Massachusetts. FDA comparability approval for these materials is required before commercialization.
Risks and Contingencies
- Regulatory Approval: NeoCart is not approved for sale. Success depends on the Phase 3 trial demonstrating superiority over microfracture (the current standard of care).
- Manufacturing Risks: Delays in FDA approval of the new manufacturing facility or raw material comparability could delay the clinical trial or commercialization.
- Capital Requirements: The company expects to incur substantial losses for several years and may require additional financing beyond 2017.
- Intellectual Property: Reliance on licensed technology from third parties (e.g., Angiotech, Stanford, Yeda) involves royalty obligations and potential termination risks.
Investor Verification Checklist
- Phase 3 Enrollment Status: Verify the current number of patients enrolled in the NeoCart Phase 3 trial against the target of 245 patients.
- Manufacturing Comparability: Confirm the status of the FDA review regarding the comparability of raw materials produced at the new Lexington facility versus those used in clinical trials.
- Cash Burn Rate: Monitor quarterly cash usage to validate the "middle of 2017" runway estimate.
- Intrexon Collaboration: Review the progress and cost implications of the Exclusive Channel Collaboration Agreement with Intrexon Corporation.
- Patent Expirations: Review the expiration dates of key licensed patents (ranging from 2014 to 2030) to assess long-term protection.